Opus Genetics (R3X1) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

R3X1 Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Opus

Genetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

R3X1 Stock 12 Month Forecast

Average Price Target

€9.14

▲(191.17% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Opus Genetics in the last 3 months. The average price target is €9.14 with a high forecast of €12.89 and a low forecast of €6.88. The average price target represents a 191.17% change from the last price of €3.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","13":"€13","3.25":"€3.25","6.5":"€6.5","9.75":"€9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.8934102,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€12.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.14259996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€9.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.87648544,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€6.88</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.24,3.9825700153846153,4.72514003076923,5.467710046153846,6.2102800615384615,6.9528500769230765,7.6954200923076925,8.437990107692308,9.180560123076923,9.923130138461538,10.665700153846153,11.408270169230768,12.150840184615385,{"y":12.8934102,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.24,3.694046150769231,4.148092301538462,4.602138452307693,5.0561846030769235,5.5102307538461535,5.964276904615385,6.418323055384615,6.872369206153847,7.326415356923077,7.780461507692308,8.234507658461538,8.688553809230768,{"y":9.14259996,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.24,3.5197296492307695,3.7994592984615387,4.079188947692308,4.358918596923077,4.6386482461538465,4.918377895384616,5.198107544615384,5.477837193846154,5.757566843076923,6.037296492307693,6.317026141538461,6.5967557907692305,{"y":6.87648544,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.022,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.958,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.706,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.656,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.695,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.055,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.16,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€12.89

Average Price Target€9.14

Lowest Price Target€6.88

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Caufield

H.C. Wainwright

€6.88

Buy

119.00%

Upside

Reiterated

09/08/26

Analysts Are Bullish on These Healthcare Stocks: Rigel (RIGL), Opus Genetics (IRD)

Francois Brisebois

LifeSci Capital

€8.6

Buy

173.75%

Upside

Reiterated

09/02/26

Analysts Offer Insights on Healthcare Companies: Opus Genetics (NASDAQ: IRD) and TScan Therapeutics (NASDAQ: TCRX)

Yun Zhong

Wedbush

€8.6

Buy

173.75%

Upside

Reiterated

09/02/26

Analysts Offer Insights on Healthcare Companies: Opus Genetics (NASDAQ: IRD), Fractyl Health, Inc. (NASDAQ: GUTS) and Dogwood Therapeutics (NASDAQ: DWTX)

Debanjana Chatterjee

JonesTrading

€8.6

Buy

173.75%

Upside

Reiterated

08/28/26

Opus Genetics: Buy Rating Reiterated on Upcoming Clinical Catalysts and Solid Cash Runway; $10 Price Target Maintained

Steven Seedhouse

Cantor Fitzgerald

€12.89

Buy

310.62%

Upside

Reiterated

08/20/26

Analysts Are Bullish on These Healthcare Stocks: Evaxion Biotech (EVAX), Opus Genetics (IRD)

Biren Amin

Piper Sandler

€9.46

Buy

201.12%

Upside

Reiterated

08/07/26

Opus Genetics (IRD) Receives a Buy from Piper Sandler

James Molloy

Alliance Global Partners

€7.74

Buy

146.37%

Upside

Reiterated

08/07/26

Alliance Global Partners Remains a Buy on Opus Genetics (IRD)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

08/06/26

Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028

Lisa Walter

RBC Capital

€8.6→€7.74

Buy

146.37%

Upside

Reiterated

08/06/26

Opus Genetics (IRD) Gets a Buy from RBC Capital

Thomas Shrader

BTIG

€10.31

Buy

228.49%

Upside

Reiterated

08/03/26

Opus Genetics: Advancing Gene Therapy Pipeline and Key 2026 Catalyst Support Buy Rating; $12 Price Target Reiterated

Andreas Argyrides

Chardan Capital

€11.17

Buy

255.87%

Upside

Reiterated

07/06/26

Opus Genetics FDA alignment further de-risks path to market, says ChardanOpus Genetics FDA alignment further de-risks path to market, says Chardan

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

07/06/26

Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Opus Genetics (IRD)

Kostas Biliouris

Oppenheimer

€8.6

Buy

173.75%

Upside

Reiterated

06/17/26

Oppenheimer Sticks to Their Buy Rating for Opus Genetics (IRD)

Debjit Chattopadhyay

Guggenheim

€13.75

Buy

337.99%

Upside

Initiated

06/04/26

Opus Genetics initiated with a Buy at GuggenheimOpus Genetics initiated with a Buy at Guggenheim

Lili (Aurélie) Nsongo

Leerink Partners

€8.6

Buy

173.75%

Upside

Initiated

05/21/26

Opus Genetics initiated with an Outperform at LeerinkOpus Genetics initiated with an Outperform at Leerink

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Caufield

H.C. Wainwright

€6.88

Buy

119.00%

Upside

Reiterated

09/08/26

Analysts Are Bullish on These Healthcare Stocks: Rigel (RIGL), Opus Genetics (IRD)

Francois Brisebois

LifeSci Capital

€8.6

Buy

173.75%

Upside

Reiterated

09/02/26

Analysts Offer Insights on Healthcare Companies: Opus Genetics (NASDAQ: IRD) and TScan Therapeutics (NASDAQ: TCRX)

Yun Zhong

Wedbush

€8.6

Buy

173.75%

Upside

Reiterated

09/02/26

Analysts Offer Insights on Healthcare Companies: Opus Genetics (NASDAQ: IRD), Fractyl Health, Inc. (NASDAQ: GUTS) and Dogwood Therapeutics (NASDAQ: DWTX)

Debanjana Chatterjee

JonesTrading

€8.6

Buy

173.75%

Upside

Reiterated

08/28/26

Opus Genetics: Buy Rating Reiterated on Upcoming Clinical Catalysts and Solid Cash Runway; $10 Price Target Maintained

Steven Seedhouse

Cantor Fitzgerald

€12.89

Buy

310.62%

Upside

Reiterated

08/20/26

Analysts Are Bullish on These Healthcare Stocks: Evaxion Biotech (EVAX), Opus Genetics (IRD)

Biren Amin

Piper Sandler

€9.46

Buy

201.12%

Upside

Reiterated

08/07/26

Opus Genetics (IRD) Receives a Buy from Piper Sandler

James Molloy

Alliance Global Partners

€7.74

Buy

146.37%

Upside

Reiterated

08/07/26

Alliance Global Partners Remains a Buy on Opus Genetics (IRD)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

08/06/26

Analyst Reiterates Buy on Opus Genetics as Pivotal OPGx‑LCA5 Trial Advances and Cash Runway Extends Into 2028

Lisa Walter

RBC Capital

€8.6→€7.74

Buy

146.37%

Upside

Reiterated

08/06/26

Opus Genetics (IRD) Gets a Buy from RBC Capital

Thomas Shrader

BTIG

€10.31

Buy

228.49%

Upside

Reiterated

08/03/26

Opus Genetics: Advancing Gene Therapy Pipeline and Key 2026 Catalyst Support Buy Rating; $12 Price Target Reiterated

Andreas Argyrides

Chardan Capital

€11.17

Buy

255.87%

Upside

Reiterated

07/06/26

Opus Genetics FDA alignment further de-risks path to market, says ChardanOpus Genetics FDA alignment further de-risks path to market, says Chardan

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

07/06/26

Analysts Are Bullish on These Healthcare Stocks: CVRx (CVRX), Opus Genetics (IRD)

Kostas Biliouris

Oppenheimer

€8.6

Buy

173.75%

Upside

Reiterated

06/17/26

Oppenheimer Sticks to Their Buy Rating for Opus Genetics (IRD)

Debjit Chattopadhyay

Guggenheim

€13.75

Buy

337.99%

Upside

Initiated

06/04/26

Opus Genetics initiated with a Buy at GuggenheimOpus Genetics initiated with a Buy at Guggenheim

Lili (Aurélie) Nsongo

Leerink Partners

€8.6

Buy

173.75%

Upside

Initiated

05/21/26

Opus Genetics initiated with an Outperform at LeerinkOpus Genetics initiated with an Outperform at Leerink

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ONCBeOne Medicines

DNLIDenali Therapeutics

SNDXSyndax Pharmaceuticals

ZYMEZymeworks

PTGXProtagonist Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Opus Genetics

3 Months

Albert LoweCraig-Hallum

Success Rate

9/11 ratings generated profit

Average Return

+31.61%

Copying Albert Lowe's trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +31.61% per trade.

1 Year

Debanjana ChatterjeeJonesTrading

Success Rate

17/17 ratings generated profit

Average Return

+138.48%

Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +138.48% per trade.

2 Years

Debanjana ChatterjeeJonesTrading

Success Rate

17/17 ratings generated profit

Average Return

+196.21%

Copying Debanjana Chatterjee's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +196.21% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

R3X1 Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, R3X1 has received 26 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. R3X1 average Analyst price target in the past 3 months is 9.14.

Each month's total comprises the sum of three months' worth of ratings.

R3X1 Financial Forecast

R3X1 Earnings Forecast

Next quarter’s earnings estimate for R3X1 is -€0.13 with a range of -€0.15 to -€0.04. The previous quarter’s EPS was -€0.12. R3X1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year R3X1 has Performed in-line its overall industry.

R3X1 Sales Forecast

Next quarter’s sales forecast for R3X1 is €1.41M with a range of €0.00 to €3.10M. The previous quarter’s sales results were €649.76K. R3X1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year R3X1 has Performed in-line its overall industry.

R3X1 Stock Forecast FAQ

What is DE:R3X1’s average 12-month price target, according to analysts?

Based on analyst ratings, Opus Genetics’s 12-month average price target is 9.14.

What is DE:R3X1’s upside potential, based on the analysts’ average price target?

Opus Genetics has 191.17% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Opus Genetics a Buy, Sell or Hold?

Opus Genetics has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Opus Genetics’s share price target?

The average share price target for Opus Genetics is 9.14. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €12.89 ,and the lowest forecast is €6.88. The average share price target represents 191.17% Increase from the current price of €3.14.

What do analysts say about Opus Genetics?

Opus Genetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Opus Genetics?

To buy shares of DE:R3X1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Opus Genetics (R3X1) Stock Forecast & Price Target

R3X1 Analyst Ratings

R3X1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Opus Genetics

R3X1 Analyst Recommendation Trends

R3X1 Financial Forecast

R3X1 Earnings Forecast

R3X1 Sales Forecast

R3X1 Stock Forecast FAQ

Detailed List of Analyst Forecasts